Aegerion’s Lomitapide Gets Standard Review For Rare Genetic Cholesterol Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Aegerion is preparing for an advisory committee meeting after submitting its LDL-C lowering oral drug lomitapide to FDA for patients with homozygous familial hypercholesterolemia. The NDA was submitted ahead of that for Isis/Genzyme’s injectable competitor, mipomersen.
You may also be interested in...
Panel Review Of Aegerion’s Lomitapide May Lead To Evolution Of Cholesterol Drug Approval Standards
FDA will be using an upcoming advisory panel review of Aegerion Pharmaceuticals Inc.’s lomitapide to see if there is still support for traditional lipid endpoints in clinical trials of cholesterol drugs.
Was Enobia’s Sale A High Water Mark For Rare Disease Deals?
Alexion’s “hotly contested” purchase of Enobia last December didn’t get much attention, but it marked a watershed year for rare disease drug deals. Will high drug prices, skittish regulators and a gold-rush push by Big Pharma start to sour the sector?
Financings Of The Fortnight Ponders The Potential Of Mapping The Microbiome
Plus news on recent financial activity by Tesaro, Omeros, Neviah Genomics and Aegerion Pharmaceuticals.